Unique Approach

- Antibacterial
- Antifungal
- Resistance Breaker
- Antibiofilm

Attacking AMR Globally
- Polymicrobial (fungal)
- Biofilm
First-in-Class Candidates

**Antibacterial**
- Novarifyn® NP432
  - Preclinical bactericidal peptide
  - MDR bacterial infections, sepsis

**Antifungal**
- Novamycin® NP339
  - Clinical stage fungicidal peptide
  - Aspergillosis

**Resistance Breaker**
- Nylexa™ NM002/Lynovex® NM001
  - Late clinical stage (CF); NM001
  - Antibiotic chemopotentiation & AMR reversal; NM002

**Antibiofilm**
- Lynovex® NM001
  - Late stage clinical (CF)
  - Bacterial & fungal biofilms

- Novel, intelligently designed biological therapies
- Agnostic WRT resistance status
- MOA mitigates/negates development of future resistance
Tackling AMR with an approach recognising the complexity/global nature of the problem & with novel drug candidates that circumvent existing & prevent/mitigate future AMR.